EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Effects of combined treatment with eldecalcitol and alendronate on bone mass, mechanical properties, and bone histomorphometry in ovariectomized rats: a comparison with alfacalcidol and alendronate



Effects of combined treatment with eldecalcitol and alendronate on bone mass, mechanical properties, and bone histomorphometry in ovariectomized rats: a comparison with alfacalcidol and alendronate



Bone 52(1): 181-188



Eldecalcitol (ELD), a 2?-hydroxypropyloxy derivative of 1?,25 (OH) 2D3, inhibits bone resorption more potently than alfacalcidol (ALF) while maintaining osteoblastic function in an ovariectomized (OVX) osteoporosis rat model. Alendronate (ALN), which is the most common bisphosphonate used for the treatment of osteoporosis, increases the bone mineral density (BMD) by suppressing bone resorption. In this study, we investigated the effects of combination treatments with ELD and ALN or with ALF and ALN on bone mass and strength in OVX rats. Seventy female rats, 32weeks old, were assigned to seven groups: (1) a sham-operated control group; an OVX-control group; an ELD group; an ALF group; an ALN group; an ELD+ALN group; and an ALF+ALN group. OVX rats were orally treated with ELD (0.015?g/kg), ALF (0.0375?g/kg), or ALN (0.2mg/kg) daily for 12weeks. In both the lumbar spine and the femur, ELD and ALF monotherapy significantly increased the BMD, and ELD+ALN and ALF+ALN significantly increased the BMD, compared with ALN monotherapy, as an additive effect. In particular, ELD+ALN resulted in a significantly higher BMD than ALF+ALN in the femur. On mechanical testing of the lumbar spine, ELD and ALF monotherapy significantly increased the ultimate load, and ELD+ALN and ALF+ALN significantly increased the ultimate load compared with ALN monotherapy. In the femur, ELD, ELD+ALN, and ALF+ALN treatment significantly increased the ultimate load, compared with the OVX-control group, and ELD+ALN resulted in a significantly higher ultimate load than ALN monotherapy. A histomorphometric analysis showed that ELD monotherapy and ELD+ALN combination therapy had a potent inhibitory effect on bone resorption parameters (osteoclast surface and eroded surface), while maintaining bone formation parameters (osteoblast surface and osteoid surface). By contrast, ALF and ALF+ALN significantly lowered the histological parameters of both bone resorption and formation. These results suggested that ELD or ALF used in combination with ALN has therapeutic advantages over ALN monotherapy, with ELD+ALN combination treatment producing an especially beneficial anti-osteoporotic effect by inhibiting osteoclastic bone resorption and maintaining osteoblastic function, compared with ALF+ALN combination treatment. The effects of combination treatments with Eldecalcitol and Alendronate or alfacalcidol and Alendronate are examined in ovariectomized rats. Eldecalcitol with Alendronate therapy inhibits bone resorption, while maintaining bone formation by histomorphometric analysis. Alfacalcidol with Alendronate therapy inhibits the histological parameters of both bone resorption and formation. This study suggests Eldecalcitol with Alendronate therapy has therapeutic advantages over Alfacalcidol with Alendronate therapy.

(PDF emailed within 0-6 h: $19.90)

Accession: 036602242

Download citation: RISBibTeXText

PMID: 23041510

DOI: 10.1016/j.bone.2012.09.031



Related references

Comparative effects of alendronate and alfacalcidol on cancellous and cortical bone mass and bone mechanical properties in ovariectomized rats. Experimental Animals 55(4): 357-367, 2006

Beneficial effects of combined administration of alendronate and alfacalcidol on cancellous bone mass of the tibia in orchidectomized rats: a bone histomorphometry study. Journal of Nutritional Science and Vitaminology 54(1): 11-17, 2008

Comparative therapeutic effects of alendronate and alfacalcidol on cancellous and cortical bone mass and mechanical properties in ovariectomized osteopenic rats. Journal of Nutritional Science and Vitaminology 52(1): 1-8, 2006

Effects of combined prostaglandin and alendronate treatment on the histomorphometry and biomechanical properties of bone in ovariectomized rats. Journal of Bone and Mineral Research 8(7): 871-879, 1993

Effects of continuous alendronate treatment on bone mass and mechanical properties in ovariectomized rats: comparison with pamidronate and etidronate in growing rats. Journal of Pharmacology and Experimental Therapeutics 286(1): 128-135, 1998

Treatment of renal transplant recipients with low bone mineral density: a randomized prospective trial of alendronate, alfacalcidol, and alendronate combined with alfacalcidol. Transplantation Proceedings 40(1): 160-166, 2008

Additive effects of combined treatment with etidronate and alfacalcidol on bone mass and mechanical properties in ovariectomized rats. Bone (New York) 27(5): 647-654, November, 2000

The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. Journal of Clinical Investigation 92(6): 2577-2586, 1993

Effects of suppressed bone remodeling by minodronic acid and alendronate on bone mass, microdamage accumulation, collagen crosslinks and bone mechanical properties in the lumbar vertebra of ovariectomized cynomolgus monkeys. Bone 97: 184-191, 2017

Effects of denosumab, alendronate, or denosumab following alendronate on bone turnover, calcium homeostasis, bone mass and bone strength in ovariectomized cynomolgus monkeys. Journal of Bone and Mineral Research 30(4): 657-669, 2016

Effect of 17beta-estradiol or alendronate on the bone densitometry, bone histomorphometry and bone metabolism of ovariectomized rats. Brazilian Journal of Medical and Biological Research 34(8): 1015-1022, 2001

Effects of alendronate and alfacalcidol on the femoral bone mass and bone strength in orchidectomized rats. Chinese Journal of Physiology 51(6): 331-337, 2009

Alendronate (ALN) combined with osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats. Journal of Orthopaedic Surgery and Research 6: 34-34, 2012

Comparison of effects of alfacalcidol and alendronate on mechanical properties and bone collagen cross-links of callus in the fracture repair rat model. Bone 46(4): 1170-1179, 2010

Effect of risedronate on the cortical and cancellous bone mass and mechanical properties in ovariectomized rats: a comparison with the effects of alfacalcidol. Journal of Nutritional Science and Vitaminology 52(6): 393-401, 2007